Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Ashish Srinivasan, Craig Haifer and Lena Thin
Med J Aust 2021; 215 (9): . || doi: 10.5694/mja2.51303
Published online: 1 November 2021

In reply: We thank Lim and colleagues1 for their insightful comments regarding the use biosimilar medicines in Australia; their letter highlights some pertinent issues.

  • Ashish Srinivasan1,2
  • Craig Haifer3,4
  • Lena Thin5

  • 1 Eastern Health, Melbourne, VIC
  • 2 Monash University, Melbourne, VIC
  • 3 St Vincent’s Hospital Sydney, Sydney, NSW
  • 4 University of Sydney, Sydney, NSW
  • 5 Fiona Stanley Hospital, Perth, WA



Ashish Srinivasan is supported by an Australian Government Research Training Program scholarship and Monash Graduate Excellence scholarship

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.